Anupam Dalal

Biography

Anupam is a managing director at Kearny Venture Partners and founder and managing member of KVP Capital. Anupam is a board member of Aerpio Therapeutics, Akebia Therapeutics (AKBA), Neurotech, NewBridge Pharmaceuticals, and Nora Therapeutics. He led Kearny's investments in Nextwave Pharmaceuticals. Prior to joining Kearny, Anupam worked at Flagship Ventures. At Flagship, he was a board member with Resolvyx Pharmaceuticals and Pervasis (acquired by Shire) and an observer at CGI Pharmaceuticals (acquired by Gilead), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Acceleron Pharma (XLRN). Anupam received his M.D. from the University of California, San Francisco, with honors. Anupam was Resident in Surgery at Brigham and Women's Hospital / Harvard Medical School. He received an MBA from Harvard Business School, with Distinction, and a BA (Phi Beta Kappa) in Economics summa cum laude from the University of California at Berkeley.

Research Interest

Anupam is a managing director at Kearny Venture Partners and founder and managing member of KVP Capital. Anupam is a board member of Aerpio Therapeutics, Akebia Therapeutics (AKBA), Neurotech, NewBridge Pharmaceuticals, and Nora Therapeutics. He led Kearny's investments in Nextwave Pharmaceuticals. Prior to joining Kearny, Anupam worked at Flagship Ventures. At Flagship, he was a board member with Resolvyx Pharmaceuticals and Pervasis (acquired by Shire) and an observer at CGI Pharmaceuticals (acquired by Gilead), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Acceleron Pharma (XLRN). Anupam received his M.D. from the University of California, San Francisco, with honors. Anupam was Resident in Surgery at Brigham and Women's Hospital / Harvard Medical School. He received an MBA from Harvard Business School, with Distinction, and a BA (Phi Beta Kappa) in Economics summa cum laude from the University of California at Berkeley.